Partners For Kids Communication
This Partners For Kids’ toolkit is designed to help health care professionals regarding nirsevimab, the Respiratory Syncytial Virus (RSV) monoclonal antibody product. The toolkit includes resources for providers and patients that can be used to support decision-making and patient understanding. The information is updated regularly based on current clinical guidelines, recommendations, and data.
Resources for Health Care Professionals:
-
- RSV Immunization Frequently Asked Questions (AAP)
- RSV-Immunization-Adminstration-Visual-Guide.pdf
- Beyfortus (nirsevimab) specifics:
- Enflonsia (clesrovimab-cfor) specifics:
- Recommendations for the Prevention of Respiratory Syncytial Virus Disease in Infants and Children: Technical Report | Pediatrics | American Academy of Pediatrics
RSV Immunization Implementation Logistics
Partners for Kids Resources
- 2024 Webinar Video: Update on Immunization Practices for Prevention of Severe RSV Infection
- 2024 Webinar Slide Deck: Update on Immunization Practices for Prevention of Severe RSV Infection
- 2026 notes:
- Only children 8 through 19 months who meet high-risk criteria should receive RSV immunization in their second RSV season (see 2026 updated inclusion criteria). Nirsevimab is approved for this indication; clesrovimab is not.
- Clesrovimab is not indicated for use in adults.
- Palivizumab is no longer routinely recommended for use and will be discontinued as of December 31, 2025.
- 2026 notes:
Maternal RSV Vaccine Resources
Resources for Patient and Families